because they are a small company with limited resources. They had difficulty getting funding for the rets trial until Acadia came along, and decided their best option was to concentrate on small unmet needs. Trials for wider conditions would be very expensive and prone to failure.
have a look at other post about their history they may give a better understanding
Ann: Investor Presentation, 14 March 2023, page-77
-
- There are more pages in this discussion • 69 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.62 |
Change
-0.450(3.20%) |
Mkt cap ! $1.737B | |||
| Open | High | Low | Value | Volume |
| $13.73 | $13.88 | $13.40 | $5.885M | 429.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 1010 | $13.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.64 | 530 | 15 |
View Market Depth
| Last trade - 14.16pm 04/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |